JP2014505015A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505015A5
JP2014505015A5 JP2013537131A JP2013537131A JP2014505015A5 JP 2014505015 A5 JP2014505015 A5 JP 2014505015A5 JP 2013537131 A JP2013537131 A JP 2013537131A JP 2013537131 A JP2013537131 A JP 2013537131A JP 2014505015 A5 JP2014505015 A5 JP 2014505015A5
Authority
JP
Japan
Prior art keywords
interferon
therapeutic agent
additional therapeutic
teriflunomide
fingolimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505015A (ja
JP5903438B2 (ja
Filing date
Publication date
Priority claimed from GB1018519.7A external-priority patent/GB2485169A/en
Application filed filed Critical
Publication of JP2014505015A publication Critical patent/JP2014505015A/ja
Publication of JP2014505015A5 publication Critical patent/JP2014505015A5/ja
Application granted granted Critical
Publication of JP5903438B2 publication Critical patent/JP5903438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537131A 2010-11-03 2011-11-03 多発性硬化症(ms)の新規の治療 Expired - Fee Related JP5903438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (3)

Publication Number Publication Date
JP2014505015A JP2014505015A (ja) 2014-02-27
JP2014505015A5 true JP2014505015A5 (cg-RX-API-DMAC10.html) 2014-10-23
JP5903438B2 JP5903438B2 (ja) 2016-04-13

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537131A Expired - Fee Related JP5903438B2 (ja) 2010-11-03 2011-11-03 多発性硬化症(ms)の新規の治療

Country Status (10)

Country Link
US (1) US20130309199A1 (cg-RX-API-DMAC10.html)
EP (1) EP2635271A1 (cg-RX-API-DMAC10.html)
JP (1) JP5903438B2 (cg-RX-API-DMAC10.html)
KR (1) KR101877587B1 (cg-RX-API-DMAC10.html)
CN (1) CN103209692A (cg-RX-API-DMAC10.html)
BR (1) BR112013010883A2 (cg-RX-API-DMAC10.html)
CA (1) CA2816911C (cg-RX-API-DMAC10.html)
GB (1) GB2485169A (cg-RX-API-DMAC10.html)
RU (1) RU2595861C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012059541A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
AU2018368332B2 (en) 2017-11-14 2022-05-12 Merck Sharp & Dohme Llc Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク エンド カムパニー インコーポレーテッド Aβ42低下薬としてのジェミナル二置換NSAID誘導体
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체

Similar Documents

Publication Publication Date Title
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
EA201070182A1 (ru) Алкилсульфонилзамещённые тиазолидные соединения
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
CR20130409A (es) Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
HUE056636T2 (hu) Cisz-1,1,1,4,4,4-hexafluor-2-butén azeotróp-jellegû készítményei
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
MX370085B (es) Compuestos de piridazinona y usos de los mismos.
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
GEP20186885B (en) Novel compounds
JP2011519825A5 (cg-RX-API-DMAC10.html)
MX349802B (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
HK1198358A1 (en) Sustained release composition of prostacyclin
IN2014CN00572A (cg-RX-API-DMAC10.html)
MX350793B (es) Pirroldicarboxamidas condensadas y su uso como agentes farmaceuticos.
CY1121696T1 (el) Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
UA107592C2 (uk) Композиція для боротьби з захворюваннями рослин і її застосування
WO2016191363A8 (en) Combination hiv therapeutic
EP2738158A4 (en) METAL-SALEN COMPLEX CONNECTION, LOCAL ANESTHETICS AND MEDIUM AGAINST MALIGNANT TUMORS
EA201290954A1 (ru) Композиция для топического применения
UA113806C2 (xx) Пероральний препарат для лікування серцево-судинних захворювань